» Articles » PMID: 21349098

Mycobacterium Tuberculosis and the Intimate Discourse of a Chronic Infection

Overview
Journal Immunol Rev
Date 2011 Feb 26
PMID 21349098
Citations 144
Authors
Affiliations
Soon will be listed here.
Abstract

Mycobacterium tuberculosis is an extremely successful pathogen that demonstrates the capacity to modulate its host both at the cellular and tissue levels. At the cellular level, the bacterium enters its host macrophage and arrests phagosome maturation, thus avoiding many of the microbicidal responses associated with this phagocyte. Nonetheless, the intracellular environment places certain demands on the pathogen, which, in response, senses the environmental shifts and upregulates specific metabolic programs to allow access to nutrients, minimize the consequences of stress, and sustain infection. Despite its intracellular niche, Mycobacterium tuberculosis demonstrates a marked capacity to modulate the tissues surrounding infected cells through the release of potent, bioactive cell wall constituents. These cell wall lipids are released from the host cell by an exocytic process and induce physiological changes in neighboring phagocytes, which drives formation of a granuloma. This tissue response leads to the generation and accumulation of caseous debris and the progression of the human tuberculosis granuloma. Completion of the life cycle of tuberculosis requires damaging the host to release infectious bacteria into the airways to spread the infection. This damage reflects the pathogen's ability to subvert the host's innate and acquired immune responses to its own nefarious ends.

Citing Articles

A bacterial effector manipulates host lysosomal protease activity-dependent plasticity in cell death modalities to facilitate infection.

Lu Z, Zhang Y, Zhong Y, Qiang L, Ge P, Lei Z Proc Natl Acad Sci U S A. 2025; 122(8):e2406715122.

PMID: 39964716 PMC: 11874418. DOI: 10.1073/pnas.2406715122.


Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.

Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D Front Immunol. 2024; 15:1427559.

PMID: 39717773 PMC: 11663721. DOI: 10.3389/fimmu.2024.1427559.


Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.

Sarathy J PLoS Pathog. 2024; 20(10):e1012595.

PMID: 39383167 PMC: 11463790. DOI: 10.1371/journal.ppat.1012595.


Mononuclear Phagocytes, Cellular Immunity, and Nobel Prizes: A Historic Perspective.

Gordon S, Roberti A, Kaufmann S Cells. 2024; 13(16).

PMID: 39195266 PMC: 11352343. DOI: 10.3390/cells13161378.


Recent Biochemical Advances in Antitubercular Drugs: Challenges and Future.

Jain A, Kumar R, Mothsra P, Sharma A, Singh A, Kumar Y Curr Top Med Chem. 2024; 24(21):1829-1855.

PMID: 38919089 DOI: 10.2174/0115680266286294240610102911.


References
1.
Verges M, Bensadoun A, Herz J, Belcher J, Havel R . Endocytosis of hepatic lipase and lipoprotein lipase into rat liver hepatocytes in vivo is mediated by the low density lipoprotein receptor-related protein. J Biol Chem. 2004; 279(10):9030-6. DOI: 10.1074/jbc.M312908200. View

2.
Sugii S, Reid P, Ohgami N, Du H, Chang T . Distinct endosomal compartments in early trafficking of low density lipoprotein-derived cholesterol. J Biol Chem. 2003; 278(29):27180-9. DOI: 10.1074/jbc.M300542200. View

3.
Busch R, Doebele R, Patil N, Pashine A, Mellins E . Accessory molecules for MHC class II peptide loading. Curr Opin Immunol. 2000; 12(1):99-106. DOI: 10.1016/s0952-7915(99)00057-6. View

4.
North R, Jung Y . Immunity to tuberculosis. Annu Rev Immunol. 2004; 22:599-623. DOI: 10.1146/annurev.immunol.22.012703.104635. View

5.
Schnappinger D, Schoolnik G, Ehrt S . Expression profiling of host pathogen interactions: how Mycobacterium tuberculosis and the macrophage adapt to one another. Microbes Infect. 2006; 8(4):1132-40. DOI: 10.1016/j.micinf.2005.10.027. View